Advertisement Pharmaceutical Business review - Page 279 of 5269 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 15, 2026

Lilly to acquire CrossBridge Bio for up to $300m

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, comprising an upfront payment and a milestone payment tied to specified development progress.

Lilly will acquire all CrossBridge Bio shares for up to $300m, including an upfront and milestone payment, based on progress. Credit: JHVEPhoto / Shutterstock.com.